The first blood transfusions in humans were xenotransfusions, carried out by Jean-Baptiste Denis beginning in 1667. Richard Lower, Matthäus Purmann and Georges Mercklin also experimented with the use of animal blood for transfusion until this practice was forbidden in 1670, after the death of one of Denis's patients. In the middle of the 19th century, xenotransfusion was rescued from oblivion by the work of Pierre Cyprien Oré. Franz Gesellius and Oscar Hasse fervently defended xenotransfusion, but Emil Ponfick and Leonard Landois stressed the potentially harmful effects of inter-species transfusion from 1874 onward. Xenotransfusion was abandoned completely following the discovery of blood groups by Karl Landsteiner in 1900. From 2000, because of progress in xenotransplantation and the need of blood supply, xenotransfusion is again being considered. Pigs are the best potential donors. The development of alpha-1,3-galactosyltransferase gene-knockout pigs has overcome the first hurdle to xenotransfusion. The main obstacle to porcine red blood cell transfusion is now the cellular response involving macrophages or natural killer cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-3089.2007.00404.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generation and characterization of genetically modified pigs with GGTA1/β4GalNT2/CMAH knockout and human CD55/CD47 expression for xenotransfusion studies.
Sci Rep
December 2024
Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, 211166, China.
Pig red blood cells (pRBCs) represent a promising alternative to address the shortage in transfusion medicine. Nonetheless, a major obstacle to their clinical implementation is immunological rejection. In this study, we generated transgenic pigs expressing human CD47 (hCD47) and CD55 (hCD55) in α1,3-galactosyltransferase KO/β-1,4-N-acetyl-galactosaminyl transferase 2 KO/cytidine monophosphate-N-acetylneuraminic acid hydroxylase KO (TKO) pigs using CRISPR/Cas9 technology.
View Article and Find Full Text PDFInvestigation of the efficacy and safety of wild- type and triple-gene knockout pig RBC transfusions in nonhuman primates.
Front Immunol
July 2024
Department of Laboratory Medicine, Hallym University College of Medicine and Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Article Synopsis
- Decreasing blood donation rates have created a need for alternative sources, leading to the exploration of genetically engineered pig red blood cells (pRBCs), particularly triple-gene knockout (TKO) versions, for human transfusion compatibility.
- In a study involving nonhuman primates, both wild-type (WT) and TKO-pRBC transfusions significantly improved red blood cell counts initially, but triggered the body's immune response, leading to rapid antibody production and liver function impairment.
- While initial hematological improvements were noted on the first day post-transfusion, both pRBC types showed diminished circulation benefits and increased adverse reactions upon subsequent transfusions, raising concerns about their long-term efficacy in humans.
Major crossmatch compatibility of rabbit blood with rabbit, canine, and feline blood.
J Vet Emerg Crit Care (San Antonio)
April 2024
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Objective: To evaluate the major crossmatch compatibility between rabbit recipients, rabbit donors, and the major canine and feline blood types.
Design: Prospective in vitro study in December 2021.
Setting: Academic veterinary teaching hospital.
Biological response of nonhuman primates to controlled levels of acute blood loss.
Front Immunol
January 2024
Department of Laboratory Medicine, Hallym University College of Medicine and Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Introduction: The global shortage of human blood for medical use has prompted the development of alternative blood sources. Nonhuman primates (NHPs) are commonly used owing to their physiological similarities to humans. The objective of the current study was to establish a controlled-blood-loss model in NHPs to explore their clinical and biological responses.
View Article and Find Full Text PDFFuture prospects for the clinical transfusion of pig red blood cells.
Blood Rev
September 2023
Center for Transplantation Science, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Transfusion of allogeneic human red blood cell (hRBCs) is limited by supply and compatibility between individual donors and recipients. In situations where the blood supply is constrained or when no compatible RBCs are available, patients suffer. As a result, alternatives to hRBCs that complement existing RBC transfusion strategies are needed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!